Link to PDF (annalsofoncology.org) 233P – Breast Cancer Organoids Mimic Disease Heterogeneity, Allow High-Throughput Drug Screening and Show Correlation with Clinical Response Abstract 233P Background Breast
Invitrocue Chief Scientific Officer, Dr. Zahra Dantes, will be presenting our latest findings on our current validation study regarding breast cancer at ESMO Breast Cancer
The drug discovery ecosystem is changing rapidly. The rise of robotics and AI enables the emergence of a new model of data-driven drug discovery. Bringing